466 related articles for article (PubMed ID: 19490064)
1. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.
Masuda D; Nakagawa-Toyama Y; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Sandoval JC; Ohama T; Nishida M; Ishigami M; Yamashita S
Eur J Clin Invest; 2009 Aug; 39(8):689-98. PubMed ID: 19490064
[TBL] [Abstract][Full Text] [Related]
2. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
[TBL] [Abstract][Full Text] [Related]
4. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.
Bozzetto L; Annuzzi G; Corte GD; Patti L; Cipriano P; Mangione A; Riccardi G; Rivellese AA
Atherosclerosis; 2011 Jul; 217(1):142-8. PubMed ID: 21481394
[TBL] [Abstract][Full Text] [Related]
5. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.
Lee SH; Park S; Kang SM; Jang Y; Chung N; Choi D
J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):65-71. PubMed ID: 21386036
[TBL] [Abstract][Full Text] [Related]
6. Implications of decreased serum adiponectin for type IIb hyperlipidaemia and increased cholesterol levels of very-low-density lipoprotein in type II diabetic patients.
Yoshida H; Hirowatari Y; Kurosawa H; Tada N
Clin Sci (Lond); 2005 Sep; 109(3):297-302. PubMed ID: 15907189
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein (CETP) increases postprandial triglyceridaemia and delays triacylglycerol plasma clearance in transgenic mice.
Salerno AG; Patrício PR; Berti JA; Oliveira HC
Biochem J; 2009 May; 419(3):629-34. PubMed ID: 19191759
[TBL] [Abstract][Full Text] [Related]
8. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial.
Olijhoek JK; Hajer GR; van der Graaf Y; Dallinga-Thie GM; Visseren FL
J Cardiovasc Pharmacol; 2008 Aug; 52(2):145-50. PubMed ID: 18670365
[TBL] [Abstract][Full Text] [Related]
9. Dietary cholesterol, cholesterol absorption, postprandial lipemia and atherosclerosis.
Huff MW
Can J Clin Pharmacol; 2003; 10 Suppl A():26A-32A. PubMed ID: 14571303
[TBL] [Abstract][Full Text] [Related]
10. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.
Tremblay AJ; Lamarche B; Cohn JS; Hogue JC; Couture P
Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1101-6. PubMed ID: 16528005
[TBL] [Abstract][Full Text] [Related]
11. Impact of postprandial lipaemia on low-density lipoprotein (LDL) size and oxidized LDL in patients with coronary artery disease.
Granér M; Kahri J; Nakano T; Sarna SJ; Nieminen MS; Syvänne M; Taskinen MR
Eur J Clin Invest; 2006 Nov; 36(11):764-70. PubMed ID: 17032343
[TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Olijhoek JK; Visseren FL
Clin Endocrinol (Oxf); 2008 Dec; 69(6):870-7. PubMed ID: 18394022
[TBL] [Abstract][Full Text] [Related]
13. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Visseren FL
Atherosclerosis; 2009 Jan; 202(1):216-24. PubMed ID: 18533158
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe treatment of pediatric patients with hypercholesterolemia.
Clauss S; Wai KM; Kavey RE; Kuehl K
J Pediatr; 2009 Jun; 154(6):869-72. PubMed ID: 19230898
[TBL] [Abstract][Full Text] [Related]
15. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M
Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
17. [Postprandial changes of blood lipid after ordinary Chinese diet and the influencing factors thereof].
Fu ZF; Liu ML
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):260-2. PubMed ID: 19552844
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
Guerin M; Le Goff W; Duchene E; Julia Z; Nguyen T; Thuren T; Shear CL; Chapman MJ
Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):148-54. PubMed ID: 17951324
[TBL] [Abstract][Full Text] [Related]
19. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
Ogawa S; Takeuchi K; Ito S
Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia.
Sandoval JC; Nakagawa-Toyama Y; Masuda D; Tochino Y; Nakaoka H; Kawase R; Yuasa-Kawase M; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Ohama T; Matsuyama A; Nishida M; Ishigami M; Komuro I; Yamashita S
J Atheroscler Thromb; 2010 Sep; 17(9):914-24. PubMed ID: 20543519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
